Literature DB >> 1561815

The neoplastic potential of columnar-lined (Barrett's) esophagus.

G N Tytgat1, W Hameeteman.   

Abstract

Reflux of gastric contents is the most important factor contributing to the development of a columnar-lined esophagus (CLE). CLE should be considered a "mosaic" of cells, glands, and architectural types showing variable degrees of maturation towards intestinal and gastric epithelium. Dysplasia refers to an unequivocally neoplastic alteration in the epithelium. High-grade (severe) dysplasia consists of neoplastic cellular and/or architectural changes within the columnar epithelium, without invasion through the basement membrane. The prevalence of dysplasia is usually 5% to 10%. Dysplasia has been found in the vast majority in the specialized columnar-type or intestinal-type epithelium. Adenocarcinoma in CLE is most often seen in males. At the time of diagnosis transmural tumor infiltration is found in 60% to 88% of patients, and lymph node invasion in 55% to 74% of patients. The prognosis is poor with a low 5 year survival. Estimates of incidence of cancer vary from 1 case per 52 patients years of follow-up to 1 case per 441 patient years of follow-up.

Entities:  

Mesh:

Year:  1992        PMID: 1561815     DOI: 10.1007/bf02071538

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  34 in total

1.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

Review 2.  Barrett's oesophagus or columnar epithelium of the lower oesophagus.

Authors:  P Monnier; C Fontolliet; M Savary; J B Ollyo
Journal:  Baillieres Clin Gastroenterol       Date:  1987-10

3.  Barrett's epithelium complicating lye ingestion with sparing of the distal esophagus.

Authors:  S J Spechler; E M Schimmel; J W Dalton; W Doos; J S Trier
Journal:  Gastroenterology       Date:  1981-09       Impact factor: 22.682

4.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

5.  Primary adenocarcinoma of the esophagus.

Authors:  Z Steiger; R F Wilson; L Leichman; M J Busuito; J C Rosenberg
Journal:  J Surg Oncol       Date:  1987-09       Impact factor: 3.454

6.  Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus.

Authors:  R C Haggitt; J Tryzelaar; F H Ellis; H Colcher
Journal:  Am J Clin Pathol       Date:  1978-07       Impact factor: 2.493

7.  Barrett's esophagus. Comparison of benign and malignant cases.

Authors:  D B Skinner; B C Walther; R H Riddell; H Schmidt; C Iascone; T R DeMeester
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

8.  Adenocarcinoma in Barrett's oesophagus: an overrated risk.

Authors:  A H Van der Veen; J Dees; J D Blankensteijn; M Van Blankenstein
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

9.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.

Authors:  B J Reid; R C Haggitt; C E Rubin; P S Rabinovitch
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

10.  Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  J J Thompson; K R Zinsser; H T Enterline
Journal:  Hum Pathol       Date:  1983-01       Impact factor: 3.466

View more
  10 in total

Review 1.  The surgery of complicated gastro-oesophageal reflux.

Authors:  G C O'Sullivan; M G O'Brien
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

2.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

3.  Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy.

Authors:  R F Heitmiller; M Redmond; S R Hamilton
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

4.  p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia.

Authors:  M Younes; A Ertan; L V Lechago; J R Somoano; J Lechago
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

Review 5.  Prophylactic esophagectomy in Barrett esophagus with high-grade dysplasia.

Authors:  Richard F Heitmiller
Journal:  Langenbecks Arch Surg       Date:  2003-02-20       Impact factor: 3.445

6.  Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome--an update.

Authors:  Elaine E Tseng; T T Wu; Charles J Yeo; Richard F Heitmiller
Journal:  J Gastrointest Surg       Date:  2003-02       Impact factor: 3.452

Review 7.  Role of surveillance in intestinal metaplasia of the esophagus and gastroesophageal junction.

Authors:  Guido N J Tytgat; Johanna W Van Sandick; J Jan B van Lanschot; Huug Obertop
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

Review 8.  Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management.

Authors:  H J Stein; J R Siewert
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

Review 9.  Adenosquamous carcinoma arising in Barrett's esophagus.

Authors:  Tsuyoshi Noguchi; Yuzo Uchida; Shoichi Fumoto; Shinsuke Wada; Tetsuro Sato; Shinsuke Takeno
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-12

10.  c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.